NATALI AMARADASA: Open Payments
NPI 1881000255 · MYRTLE BEACH, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,332 in 216 payments from 25 companies in 2025. Trend: 2023 $3,321 · 2024 $3,058 · 2025 $4,332
Food & beverage: $4,332
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 56 | $715 |
| Otsuka America Pharmaceutical, Inc. | 23 | $445 |
| Vanda Pharmaceuticals Inc. | 13 | $391 |
| E.R. Squibb & Sons, L.L.C. | 8 | $319 |
| Neurocrine BioSciences, Inc. | 7 | $264 |
| Alkermes, Inc. | 7 | $258 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $255 |
| Teva Pharmaceuticals USA, Inc. | 21 | $211 |
| Tris Pharma Inc | 11 | $194 |
| Collegium Pharmaceutical, Inc. | 12 | $176 |
Products named: VRAYLAR, REXULTI, COBENFY, HETLIOZ, INGREZZA, CAPLYTA, AUSTEDO XR, Jornay PM.
Industry payments across SC — which companies pay providers there.
